Melanotan 2 vs Melanotan 1: Differences and Risks

Melanotan 1 and Melanotan 2 are related names in discussions of synthetic melanocortin peptides. Similar names do not make them interchangeable substances, and claims for one product cannot establish the safety or effectiveness of another.
What the names refer to
Melanotan 2 is often abbreviated MT2. “Melanotan 1” is sometimes used in discussions of afamelanotide, but a retail item carrying that name should not be assumed to be an authorised afamelanotide medicine. The European Medicines Agency’s Scenesse record concerns a specific afamelanotide implant for erythropoietic protoporphyria under defined medical conditions. It is not an approval of retail Melanotan 1 or Melanotan 2 tanning products.
Why a faster-or-better ranking is not justified
Claims that MT2 produces a deeper tan at smaller doses, lasts longer, costs less or offers weight-loss or sexual-health benefits require reliable evidence relevant to the specific products. Product strength and identity cannot be established from marketing labels alone, so those claims cannot establish a purchasing or use recommendation.
Shared questions that matter
Ask what substance a source is describing, which formulation was studied, which outcome was measured and whether the evidence applies to the specific product under discussion. Cancer Research UK explains that Melanotan tanning products have not been shown to be safe and effective for this purpose and that a tan does not replace sun protection. For the site’s broader explanation, read Melanotan 2 science and risks and the Cancer Research UK guidance.
Read the comparison through the original records
Comparing Melanotan 1 with Melanotan 2 involves more than changing a numeral. A research paper may identify a particular synthetic analogue; a medicine record identifies an authorised product and medical purpose; a seller’s label describes an offered item. Keep those records separate when checking what a comparison actually supports.
Follow the research identifiers, not just the numeral
The early literature uses chemical identifiers alongside the familiar names. A 1997 human pharmacokinetic paper identifies its NDP-alpha-MSH preparation as melanotan-I or MT-I. The Melanotan-II pilot paper describes a cyclic heptapeptide analogue of alpha-MSH. These descriptions identify different research compounds, rather than two interchangeable spellings of one finished product.
Alpha-MSH is part of the wider hormone terminology. The MSH terminology article explains that background. A shared reference to melanocortin signalling can explain why substances appear in the same discussion, but it does not establish that their composition, formulation or evidence is identical.
When a page uses MT-I, MT-II, Melanotan I or Melanotan II, follow the cited record to see which preparation it means. If a product description leaves that identity unclear, another article’s familiar abbreviation cannot resolve it. An illustration with two names is also not an analytical test of either item shown.
Two early papers were not a head-to-head trial
The 1991 trial by Levine and colleagues investigated the NDP-alpha-MSH analogue. Its abstract describes 28 healthy white male participants, a randomised double-blind placebo comparison and serial chromaticity measurements of skin darkening. That identifies both the study population and the particular outcome being measured.
The 1996 Melanotan-II pilot involved three male volunteers and a single-blind saline/placebo comparison. Pigmentation was assessed using reflectance measurements and visual observation. The different compound, sample size and methods matter when these papers are mentioned together. Neither abstract describes assigning comparable participants to MT-I and MT-II groups to determine which is better.
Reading two positive pigmentation findings side by side does not create the missing direct comparison. A claim about a faster effect would need a consistent starting point, outcome definition and observation schedule. A claim about a more persistent effect would also need comparable follow-up. Without that context, a difference between two summaries may reflect study design rather than a difference between products.
The participants in either study should not be silently replaced by a broader population when the result is repeated. Likewise, a defined experimental preparation should not be replaced by an unrelated vial or nasal product with a similar label. The dates provide historical context; they do not turn the findings into contemporary stock verification.
Separate the active substance from the authorised implant
The EMA English product information for Scenesse concerns an afamelanotide implant. Its therapeutic indication is prevention of phototoxicity in adults with erythropoietic protoporphyria, or EPP. The record belongs to that medicine and medical purpose, rather than to every product described online using a related compound name.
There are several distinct identifiers to check: the active substance, the finished formulation, the product name and the indication. Finding a familiar substance name answers only part of that check. It does not show that a different product was manufactured to the same specification or assessed for the same use.
An EU assessment should also be described with its jurisdiction intact. It should not be paraphrased into a general statement that all Melanotan products are approved, or into a claim about a retail product’s UK status. Read the linked record for what it actually authorises instead of transferring its conclusion to a tanning advertisement.
Keep each comparative claim within its evidence
A useful comparison states the question before announcing a winner. “Stronger” might refer to a laboratory response, a stated quantity or an observed outcome. “Better value” might refer to pack price or measured contents. “Safer” is a health assertion. Those labels cannot be substituted for one another, and one supporting reference does not automatically answer them all.
For a specific claim, identify the two things being compared, the measurement, the comparison conditions and the source. If any element is missing, describe the uncertainty rather than filling it with an assumed dose conversion, percentage advantage or guaranteed result. A number on a label cannot supply the clinical comparison that a claim requires.
The historical names and research timeline provides the chronology. For current public advice, use the Cancer Research UK guidance. Neither a historical study nor a darker appearance establishes UV protection or personal suitability. This comparison is a guide to reading evidence, rather than a method for preparing, administering or choosing between tanning products.
Additional references checked: 13 November 2026.
Check whether citations represent independent comparisons
Several references can make a compound comparison look better supported than it is. The useful count is not how many links appear beside a claim, but how many independent comparisons they represent. This distinction adds another check to the historical compound records above without repeating their findings or creating an equivalence between differently named products.
Count study families rather than web references
Imagine three links: a conference abstract, a journal article and a later review. If the review discusses the same participants reported in the article, and the abstract describes that same study, the links do not represent three new groups of participants. Their different publication formats can provide useful context, but they should not multiply the underlying evidence.
A practical reading note records the study identity, population and comparison once, then attaches the related publications to that family. Overlapping author names or a similar title are clues to investigate, not proof that records are identical. Where the relationship is unclear, retain that uncertainty rather than automatically count either one study or several.
This matters especially when a comparison moves from compound names into an advertised product. Our injection-listing evidence guide follows that separate trail. A study family concerns its stated preparations; a seller’s item requires its own identity evidence. Additional citations to the same research do not bridge that gap.
Separate a shared comparator from a direct comparison
Suppose fictional Study A compares preparation X with a control, while Study B compares preparation Y with another control. The presence of a control in both studies does not make X and Y directly compared. Participants, observation methods, timing and other conditions may differ. A shared word such as placebo does not erase those differences.
A direct comparison would identify the relevant alternatives within an appropriate common design. An indirect comparison needs its own justified methods and assumptions; it is not produced by subtracting two appealing numbers from different abstracts. The EMA’s statistical-principles guidance provides general clinical-trial context, not a comparative result for these retail products.
Route terminology is another possible change of subject. Our guide to an anatomical route versus a finished medicine separates route, formulation and indication. A comparison of compounds should not acquire a conclusion about a different route merely because both records discuss pigmentation or share a familiar abbreviation.
Leave an untested difference unresolved
An unmeasured difference is not a demonstrated absence of difference. If the available records do not establish which preparation has a particular comparative effect, the answer remains unresolved. It would be equally unsupported to announce a winner or to state that the two are proven equivalent on that outcome.
The wording of the question helps prevent that mistake. Identify the substances or products, the outcome and the type of comparison before drawing a conclusion. A statement about a mechanism, a historical observation or a named authorised medicine answers only its own question. None automatically answers all questions raised by a retail comparison.
This approach preserves both useful knowledge and its limits. Historical names can be clarified, publications can be grouped and a medical record can be accurately identified, while a broader superiority claim remains unestablished. Evidence does not become less useful when its scope is stated precisely; it becomes easier to distinguish a supported fact from an unanswered comparison.
References checked: 14 November 2026.